---
document_datetime: 2025-12-02 04:58:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-adroiq.html
document_name: sugammadex-adroiq.html
version: success
processing_time: 0.1238491
conversion_datetime: 2025-12-28 01:24:06.634515
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sugammadex Adroiq

[RSS](/en/individual-human-medicine.xml/67678)

##### Authorised

This medicine is authorised for use in the European Union

sugammadex Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sugammadex Adroiq](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79584)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sugammadex Adroiq is a medicine used to reverse the effect of the muscle relaxants rocuronium and vecuronium. Muscle relaxants are medicines used during some types of operation to make the muscles relax, including the muscles that help the patient to breathe. Muscle relaxants make it easier for the surgeon to do the operation. Sugammadex Adroiq is used to speed up the recovery from the muscle relaxant, usually at the end of the operation.

Sugammadex Adroiq can be used in adults who have received rocuronium and vecuronium, and in children aged 2 years or older who have received rocuronium.

Sugammadex Adroiq is a 'generic medicine'. This means that Sugammadex Adroiq contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Sugammadex Adroiq is Bridion. For more information on generic medicines, see the question-and-answer document here.

Sugammadex Adroiq contains the active substance sugammadex.

Expand section

Collapse section

## How is Sugammadex Adroiq used?

Sugammadex Adroiq can only be obtained with a prescription. It is given by or under the supervision of an anaesthetist (a doctor specialised in anaesthesia). Sugammadex Adroiq is given into a vein as a single bolus injection (given all at once).

For more information about using Sugammadex Adroiq, see the package leaflet or contact your doctor or pharmacist.

## How does Sugammadex Adroiq work?

The active substance in Sugammadex Adroiq, sugammadex attaches to the muscle relaxants rocuronium and vecuronium, stopping them from having an effect. As a result, the muscles contract and begin to work normally again, including the muscles that help the patient to breathe.

## How has Sugammadex Adroiq been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Bridion, and do not need to be repeated for Sugammadex Adroiq.

As for every medicine, the company provided studies on the quality of Sugammadex Adroiq. There was no need for 'bioequivalence' studies to investigate whether Sugammadex Adroiq is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Sugammadex Adroiq is given by injection into a vein, so the active substance is delivered straight into the bloodstream.

## What are the benefits and risks of Sugammadex Adroiq?

Because Sugammadex Adroiq is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

For the list of side effects and restrictions with Sugammadex Adroiq, see the package leaflet.

## Why is Sugammadex Adroiq authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Sugammadex Adroiq has been shown to be comparable to Bridion. Therefore, the Agency's view was that, as for Bridion, the benefits of Sugammadex Adroiq outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sugammadex Adroiq?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sugammadex Adroiq have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sugammadex Adroiq are continuously monitored. Suspected side effects reported with Sugammadex Adroiq are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sugammadex Adroiq

Sugammadex Adroiq received a marketing authorisation valid throughout the EU on 26 May 2023.

Further information on Sugammadex Adroiq can be found on the Agency's website: www.ema.europa.eu/medicines/human/EPAR/sugammadex-adroiq. Information on the reference medicine can also be found on the Agency's website.

This overview was last updated in 05-2023.

Sugammadex Adroiq : EPAR - Medicine overview

Reference Number: EMA/162666/2023

English (EN) (143.2 KB - PDF)

**First published:** 16/06/2023

[View](/en/documents/overview/sugammadex-adroiq-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-318)

български (BG) (155.72 KB - PDF)

**First published:**

16/06/2023

[View](/bg/documents/overview/sugammadex-adroiq-epar-medicine-overview_bg.pdf)

español (ES) (134.36 KB - PDF)

**First published:**

16/06/2023

[View](/es/documents/overview/sugammadex-adroiq-epar-medicine-overview_es.pdf)

čeština (CS) (154.27 KB - PDF)

**First published:**

16/06/2023

[View](/cs/documents/overview/sugammadex-adroiq-epar-medicine-overview_cs.pdf)

dansk (DA) (133.21 KB - PDF)

**First published:**

16/06/2023

[View](/da/documents/overview/sugammadex-adroiq-epar-medicine-overview_da.pdf)

Deutsch (DE) (136.86 KB - PDF)

**First published:**

16/06/2023

[View](/de/documents/overview/sugammadex-adroiq-epar-medicine-overview_de.pdf)

eesti keel (ET) (122.63 KB - PDF)

**First published:**

16/06/2023

[View](/et/documents/overview/sugammadex-adroiq-epar-medicine-overview_et.pdf)

ελληνικά (EL) (157.91 KB - PDF)

**First published:**

16/06/2023

[View](/el/documents/overview/sugammadex-adroiq-epar-medicine-overview_el.pdf)

français (FR) (135.07 KB - PDF)

**First published:**

16/06/2023

[View](/fr/documents/overview/sugammadex-adroiq-epar-medicine-overview_fr.pdf)

hrvatski (HR) (150.67 KB - PDF)

**First published:**

16/06/2023

[View](/hr/documents/overview/sugammadex-adroiq-epar-medicine-overview_hr.pdf)

italiano (IT) (133.33 KB - PDF)

**First published:**

16/06/2023

[View](/it/documents/overview/sugammadex-adroiq-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (163.57 KB - PDF)

**First published:**

16/06/2023

[View](/lv/documents/overview/sugammadex-adroiq-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (153.78 KB - PDF)

**First published:**

16/06/2023

[View](/lt/documents/overview/sugammadex-adroiq-epar-medicine-overview_lt.pdf)

magyar (HU) (154.95 KB - PDF)

**First published:**

16/06/2023

[View](/hu/documents/overview/sugammadex-adroiq-epar-medicine-overview_hu.pdf)

Malti (MT) (155.3 KB - PDF)

**First published:**

16/06/2023

[View](/mt/documents/overview/sugammadex-adroiq-epar-medicine-overview_mt.pdf)

Nederlands (NL) (133.59 KB - PDF)

**First published:**

16/06/2023

[View](/nl/documents/overview/sugammadex-adroiq-epar-medicine-overview_nl.pdf)

polski (PL) (156.76 KB - PDF)

**First published:**

16/06/2023

[View](/pl/documents/overview/sugammadex-adroiq-epar-medicine-overview_pl.pdf)

português (PT) (134.58 KB - PDF)

**First published:**

16/06/2023

[View](/pt/documents/overview/sugammadex-adroiq-epar-medicine-overview_pt.pdf)

română (RO) (153.85 KB - PDF)

**First published:**

16/06/2023

[View](/ro/documents/overview/sugammadex-adroiq-epar-medicine-overview_ro.pdf)

slovenčina (SK) (154.83 KB - PDF)

**First published:**

16/06/2023

[View](/sk/documents/overview/sugammadex-adroiq-epar-medicine-overview_sk.pdf)

slovenščina (SL) (152.42 KB - PDF)

**First published:**

16/06/2023

[View](/sl/documents/overview/sugammadex-adroiq-epar-medicine-overview_sl.pdf)

Suomi (FI) (132.79 KB - PDF)

**First published:**

16/06/2023

[View](/fi/documents/overview/sugammadex-adroiq-epar-medicine-overview_fi.pdf)

svenska (SV) (132.59 KB - PDF)

**First published:**

16/06/2023

[View](/sv/documents/overview/sugammadex-adroiq-epar-medicine-overview_sv.pdf)

Sugammadex Adroiq : EPAR - Risk-management-plan summary

English (EN) (93.96 KB - PDF)

**First published:** 16/06/2023

[View](/en/documents/rmp-summary/sugammadex-adroiq-epar-risk-management-plan-summary_en.pdf)

## Product information

Sugammadex Adroiq : EPAR - Product Information

English (EN) (458.17 KB - PDF)

**First published:** 16/06/2023

**Last updated:** 25/09/2025

[View](/en/documents/product-information/sugammadex-adroiq-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-339)

български (BG) (566.59 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/bg/documents/product-information/sugammadex-adroiq-epar-product-information_bg.pdf)

español (ES) (461.43 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/es/documents/product-information/sugammadex-adroiq-epar-product-information_es.pdf)

čeština (CS) (490.43 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/cs/documents/product-information/sugammadex-adroiq-epar-product-information_cs.pdf)

dansk (DA) (470.88 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/da/documents/product-information/sugammadex-adroiq-epar-product-information_da.pdf)

Deutsch (DE) (485.49 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/de/documents/product-information/sugammadex-adroiq-epar-product-information_de.pdf)

eesti keel (ET) (454.74 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/et/documents/product-information/sugammadex-adroiq-epar-product-information_et.pdf)

ελληνικά (EL) (613.43 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/el/documents/product-information/sugammadex-adroiq-epar-product-information_el.pdf)

français (FR) (505.81 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/fr/documents/product-information/sugammadex-adroiq-epar-product-information_fr.pdf)

hrvatski (HR) (516.61 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/hr/documents/product-information/sugammadex-adroiq-epar-product-information_hr.pdf)

íslenska (IS) (468.64 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/is/documents/product-information/sugammadex-adroiq-epar-product-information_is.pdf)

italiano (IT) (493.1 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/it/documents/product-information/sugammadex-adroiq-epar-product-information_it.pdf)

latviešu valoda (LV) (527.26 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/lv/documents/product-information/sugammadex-adroiq-epar-product-information_lv.pdf)

lietuvių kalba (LT) (510.51 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/lt/documents/product-information/sugammadex-adroiq-epar-product-information_lt.pdf)

magyar (HU) (532.35 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/hu/documents/product-information/sugammadex-adroiq-epar-product-information_hu.pdf)

Malti (MT) (564.88 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/mt/documents/product-information/sugammadex-adroiq-epar-product-information_mt.pdf)

Nederlands (NL) (479.17 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/nl/documents/product-information/sugammadex-adroiq-epar-product-information_nl.pdf)

norsk (NO) (604.31 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/no/documents/product-information/sugammadex-adroiq-epar-product-information_no.pdf)

polski (PL) (573.28 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/pl/documents/product-information/sugammadex-adroiq-epar-product-information_pl.pdf)

português (PT) (488.25 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/pt/documents/product-information/sugammadex-adroiq-epar-product-information_pt.pdf)

română (RO) (539.88 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/ro/documents/product-information/sugammadex-adroiq-epar-product-information_ro.pdf)

slovenčina (SK) (538.63 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/sk/documents/product-information/sugammadex-adroiq-epar-product-information_sk.pdf)

slovenščina (SL) (516.53 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/sl/documents/product-information/sugammadex-adroiq-epar-product-information_sl.pdf)

Suomi (FI) (482.13 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/fi/documents/product-information/sugammadex-adroiq-epar-product-information_fi.pdf)

svenska (SV) (451.21 KB - PDF)

**First published:**

16/06/2023

**Last updated:**

25/09/2025

[View](/sv/documents/product-information/sugammadex-adroiq-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000297355 23/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sugammadex Adroiq : EPAR - All authorised presentations

English (EN) (48.91 KB - PDF)

**First published:** 16/06/2023

[View](/en/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-116)

български (BG) (65.15 KB - PDF)

**First published:**

16/06/2023

[View](/bg/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_bg.pdf)

español (ES) (48.96 KB - PDF)

**First published:**

16/06/2023

[View](/es/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_es.pdf)

čeština (CS) (64.6 KB - PDF)

**First published:**

16/06/2023

[View](/cs/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (50.48 KB - PDF)

**First published:**

16/06/2023

[View](/da/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.51 KB - PDF)

**First published:**

16/06/2023

[View](/de/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.41 KB - PDF)

**First published:**

16/06/2023

[View](/et/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.54 KB - PDF)

**First published:**

16/06/2023

[View](/el/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_el.pdf)

français (FR) (48.6 KB - PDF)

**First published:**

16/06/2023

[View](/fr/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (66.65 KB - PDF)

**First published:**

16/06/2023

[View](/hr/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (74.75 KB - PDF)

**First published:**

16/06/2023

[View](/is/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.33 KB - PDF)

**First published:**

16/06/2023

[View](/it/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (67.55 KB - PDF)

**First published:**

16/06/2023

[View](/lv/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.44 KB - PDF)

**First published:**

16/06/2023

[View](/lt/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (57.93 KB - PDF)

**First published:**

16/06/2023

[View](/hu/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (67.48 KB - PDF)

**First published:**

16/06/2023

[View](/mt/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (49.58 KB - PDF)

**First published:**

16/06/2023

[View](/nl/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (70.98 KB - PDF)

**First published:**

16/06/2023

[View](/no/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_no.pdf)

polski (PL) (68.35 KB - PDF)

**First published:**

16/06/2023

[View](/pl/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_pl.pdf)

português (PT) (49.65 KB - PDF)

**First published:**

16/06/2023

[View](/pt/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_pt.pdf)

română (RO) (65.49 KB - PDF)

**First published:**

16/06/2023

[View](/ro/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (66.75 KB - PDF)

**First published:**

16/06/2023

[View](/sk/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.26 KB - PDF)

**First published:**

16/06/2023

[View](/sl/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (47.39 KB - PDF)

**First published:**

16/06/2023

[View](/fi/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.23 KB - PDF)

**First published:**

16/06/2023

[View](/sv/documents/all-authorised-presentations/sugammadex-adroiq-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sugammadex Adroiq Active substance sugammadex sodium International non-proprietary name (INN) or common name sugammadex Therapeutic area (MeSH) Neuromuscular Blockade Anatomical therapeutic chemical (ATC) code V03AB35

### Pharmacotherapeutic group

All other therapeutic products

### Therapeutic indication

Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

## Authorisation details

EMA product number EMEA/H/C/006046 Marketing authorisation holder

Extrovis EU Ltd

Raktarvarosi Ut 9 Torokbalint 2045 Hungary

Marketing authorisation issued 26/05/2023 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sugammadex Adroiq : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (418.08 KB - PDF)

**First published:** 08/04/2025

**Last updated:** 25/09/2025

[View](/en/documents/procedural-steps-after/sugammadex-adroiq-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sugammadex Adroiq : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (105.04 KB - PDF)

**First published:** 12/10/2023

**Last updated:** 08/04/2025

[View](/en/documents/procedural-steps-after/sugammadex-adroiq-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sugammadex Adroiq : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/177188/2023

English (EN) (407.01 KB - PDF)

**First published:** 16/06/2023

[View](/en/documents/assessment-report/sugammadex-adroiq-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sugammadex Adroiq

Adopted

Reference Number: EMA/CHMP/130386/2023

English (EN) (128.49 KB - PDF)

**First published:** 31/03/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sugammadex-adroiq_en.pdf)

#### News on Sugammadex Adroiq

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-march-2023) 31/03/2023

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Sugammadex Adroiq : EPAR - Product information - tracked changes

English (EN) (111.01 KB - DOCX)

**First published:** 25/09/2025

[View](/en/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-93)

български (BG) (405.5 KB - DOC)

**First published:**

25/09/2025

[View](/bg/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_bg.doc)

español (ES) (300 KB - DOC)

**First published:**

25/09/2025

[View](/es/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_es.doc)

čeština (CS) (122.82 KB - DOCX)

**First published:**

25/09/2025

[View](/cs/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (325.5 KB - DOC)

**First published:**

25/09/2025

[View](/da/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_da.doc)

Deutsch (DE) (110.55 KB - DOCX)

**First published:**

25/09/2025

[View](/de/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (112.56 KB - DOCX)

**First published:**

25/09/2025

[View](/et/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (429 KB - DOC)

**First published:**

25/09/2025

[View](/el/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_el.doc)

français (FR) (123.02 KB - DOCX)

**First published:**

25/09/2025

[View](/fr/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (417.5 KB - DOC)

**First published:**

25/09/2025

[View](/hr/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_hr.doc)

íslenska (IS) (143.58 KB - DOCX)

**First published:**

25/09/2025

[View](/is/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_is.docx)

italiano (IT) (366 KB - DOC)

**First published:**

25/09/2025

[View](/it/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_it.doc)

latviešu valoda (LV) (395.5 KB - DOC)

**First published:**

25/09/2025

[View](/lv/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_lv.doc)

lietuvių kalba (LT) (368.5 KB - DOC)

**First published:**

25/09/2025

[View](/lt/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_lt.doc)

magyar (HU) (406 KB - DOC)

**First published:**

25/09/2025

[View](/hu/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (380 KB - DOC)

**First published:**

25/09/2025

[View](/mt/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_mt.doc)

Nederlands (NL) (335 KB - DOC)

**First published:**

25/09/2025

[View](/nl/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_nl.doc)

norsk (NO) (174.23 KB - DOCX)

**First published:**

25/09/2025

[View](/no/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_no.docx)

polski (PL) (412 KB - DOC)

**First published:**

25/09/2025

[View](/pl/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_pl.doc)

português (PT) (339 KB - DOC)

**First published:**

25/09/2025

[View](/pt/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_pt.doc)

română (RO) (119.2 KB - DOCX)

**First published:**

25/09/2025

[View](/ro/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (399.5 KB - DOC)

**First published:**

25/09/2025

[View](/sk/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_sk.doc)

slovenščina (SL) (378 KB - DOC)

**First published:**

25/09/2025

[View](/sl/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_sl.doc)

Suomi (FI) (341.5 KB - DOC)

**First published:**

25/09/2025

[View](/fi/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_fi.doc)

svenska (SV) (111.39 KB - DOCX)

**First published:**

25/09/2025

[View](/sv/documents/product-information-tracked-changes/sugammadex-adroiq-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 25/09/2025

## Share this page

[Back to top](#main-content)